Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Borderline Resectable Pancreatic Adenocarcinoma

Conditions

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma

Trial Timeline

Mar 7, 2023 → Mar 2, 2027

NCT ID

NCT05688215

About Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab

Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab is a phase 1/2 stage product being developed by Arcus Biosciences for Borderline Resectable Pancreatic Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05688215. Target conditions include Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma.

What happened to similar drugs?

0 of 4 similar drugs in Borderline Resectable Pancreatic Adenocarcinoma were approved

Approved (0) Terminated (0) Active (4)

🔄Olanzapine + placeboEli LillyPhase 3

🔄OlanzapineEli LillyPhase 3

🔄quetiapine extended-release + PlaceboAstraZenecaPhase 3

🔄Quetiapine FumarateAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05688215	Phase 1/2	Recruiting	Mar 7, 2023	Mar 2, 2027	Borderline Resectable Pancreatic Adenocarcinoma

Competing Products

12 competing products in Borderline Resectable Pancreatic Adenocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Olanzapine + placebo	Eli Lilly	Phase 3	40
olanzapine	Eli Lilly	Pre-clinical	26
Olanzapine	Eli Lilly	Phase 3	40
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate	Jiangsu Hengrui Medicine	Phase 2	31
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	27
quetiapine extended-release + Placebo	AstraZeneca	Phase 3	40
Quetiapine fumarate + Placebo	AstraZeneca	Phase 2	35
Quetiapine Fumarate	AstraZeneca	Phase 3	40
ziprasidone + Placebo	Pfizer	Phase 2	35
Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin	Bristol Myers Squibb	Phase 1	29
PD-1/PD-L1 inhibitors + Chemotherapy	BeOne Medicines	Phase 2	36
vafidemstat + Placebo	Oryzon Genomics	Phase 2	25